{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:15:08Z","timestamp":1783358108258,"version":"3.54.6"},"reference-count":83,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100031688","name":"Pfizer Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2695551","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:21:27Z","timestamp":1783354887000},"page":"1875-1897","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of nirmatrelvir\/ritonavir treatment for COVID-19 on health-related\u00a0outcomes: a global economic value systematic literature review"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7515-8548","authenticated-orcid":false,"given":"Tendai","family":"Mugwagwa","sequence":"first","affiliation":[{"name":"Global Access and Value, Pfizer Ltd","place":["Tadworth, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3372-2996","authenticated-orcid":false,"given":"Jos\u00e9","family":"Marcano Belisario","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5251-2321","authenticated-orcid":false,"given":"Louise","family":"Hartley","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-1736","authenticated-orcid":false,"given":"Nguyen Thi Nhan","family":"Phan","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6278-4969","authenticated-orcid":false,"given":"Ruth","family":"Mokgokong","sequence":"additional","affiliation":[{"name":"Global Access and Value, Pfizer Ltd","place":["Tadworth, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"e_1_3_7_2_1","unstructured":"World Health Organization. Coronavirus disease (COVID-19). 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/coronavirus-disease-(covid-19%29"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-024-02476-6"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-025-02421-8"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2601454"},{"key":"e_1_3_7_6_1","unstructured":"World Health Organization. Post COVID-19 condition (long COVID). 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/post-covid-19-condition-(long-covid%29."},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2021.08.019"},{"issue":"10","key":"e_1_3_7_8_1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.6026\/97320630018908","article-title":"Post acute CoViD-19 syndrome (PACS)\u2014Long CoViD","volume":"18","author":"Chiappelli F","year":"2022","unstructured":"Chiappelli F, Fotovat L. Post acute CoViD-19 syndrome (PACS)\u2014Long CoViD. Bioinformation. 2022;18(10):908\u2013911.","journal-title":"Bioinformation"},{"key":"e_1_3_7_9_1","unstructured":"Centers for Disease Control and Prevention. Clinical overview of long COVID. 2025. https:\/\/www.cdc.gov\/long-covid\/hcp\/clinical-overview\/index.html?CDC_AA_refVal=https%3A\/\/www.cdc.gov\/covid\/hcp\/clinical-overview\/index.html."},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/01410768231154703"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cph4.70019"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-025-00460-8"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03218-3"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s42770-024-01600-x"},{"key":"e_1_3_7_15_1","unstructured":"European Medicines Agency. COVID-19 medicines. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-medicines"},{"key":"e_1_3_7_16_1","unstructured":"US Food and Drug Administration. FDA approves first oral antiviral for treatment of COVID-19 in adults. 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-antiviral-treatment-covid-19-adults."},{"key":"e_1_3_7_17_1","unstructured":"European Medicines Agency. Paxlovid. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/paxlovid"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac443"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.19202"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00118-4"},{"key":"e_1_3_7_21_1","unstructured":"European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 28 November 2025. 2025. https:\/\/www.ecdc.europa.eu\/en\/covid-19\/variants-concern."},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1161193"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00011-7"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23612"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2579407"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7052.275"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.24348"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-025-00604-0"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70288"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1432821"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.989"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2444836"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2536974"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/jmahp12040026"},{"key":"e_1_3_7_35_1","unstructured":"Agency for Care Effectiveness. Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19. 2025. https:\/\/isomer-user-content.by.gov.sg\/68\/7c1a83d1-e4fa-4a69-9037-860be4980bed\/guidance_nirmatrelvir-ritonavir_for_mild-to-moderate_covid-19_(25_oct_2024).pdf"},{"key":"e_1_3_7_36_1","unstructured":"CDA-AMC. Canada\u2019s Drug Agency. The cost-effectiveness and budget impact of nirmatrelvir-ritonavir for COVID-19. 2025. https:\/\/www.cda-amc.ca\/sites\/default\/files\/hta-he\/HE0048_Paxlovid.pdf."},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2025.129067"},{"key":"e_1_3_7_38_1","unstructured":"Edoka I Drake T Baker P et al. A cost-effectiveness analysis of molnupiravir and Paxlovid in three African countries. medRxiv. https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2023\/07\/05\/2023.07.05.23292205.full.pdf"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.4102\/jphia.v16i1.805"},{"key":"e_1_3_7_40_1","unstructured":"National Institute for Health and Care Excellence. Nirmatrelvir plus ritonavir sotrovimab and tocilizumab for treating COVID-19. 2023. https:\/\/www.nice.org.uk\/guidance\/ta878."},{"key":"e_1_3_7_41_1","unstructured":"National Institute for Health and Care Excellence. Nirmatrelvir plus ritonavir sotrovimab and tocilizumab for treating COVID-19. 2025. https:\/\/www.nice.org.uk\/guidance\/ta878\/resources\/nirmatrelvir-plus-ritonavir-sotrovimab-and-tocilizumab-for-treating-covid19-pdf-82613679870661."},{"key":"e_1_3_7_42_1","unstructured":"Birnie E Vergouwe M Appelman B et al. E0441. Cost-effectiveness analysis of nirmatrelvir\/ritonavir for high-risk individuals with COVID-19: a modelling study. 2026. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2950590924000131?ref=pdf_download&fr=RR-2&rr=976d6d9acce81392"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf187"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.603"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.09.025"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.1800"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.632"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.11.003"},{"key":"e_1_3_7_49_1","unstructured":"ICER (Institute for Clinical and Economic Review). Special assessment of outpatient treatments for COVID-19. 2022. https:\/\/icer.org\/wp-content\/uploads\/2021\/08\/ICER_COVID_19_Final_Evidence_Report_051022.pdf."},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.22-0106"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac637"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid3002.230835"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2191067\/v1"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.12.1290"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2022034"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-024-00427-0"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.02.001"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100602"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1174879"},{"key":"e_1_3_7_60_1","unstructured":"CDA-AMC. Nirmatrelvir\/ritonavir (Paxlovid). Canada\u2019s Drug Agency reimbursement review. 2024. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2024\/SR0808_Combine_Report.pdf"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.3310\/NAFW3527"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2023.09.005"},{"key":"e_1_3_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.909"},{"key":"e_1_3_7_64_1","unstructured":"CDA-AMC. Nirmatrelvir-ritonavir (Paxlovid): CADTH reimbursement recommendation: indication for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing and who are at high risk for progression to severe COVID-19 including hospitalization or death. 2024. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2024\/SR0808%20Paxlovid%20-%20Draft%20CADTH%20Recommendation.pdf"},{"key":"e_1_3_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.464"},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01168-0"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01654-5"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.10.029"},{"key":"e_1_3_7_69_1","unstructured":"NICE. 2025. Changes to NICE\u2019s cost-effectiveness thresholds confirmed. https:\/\/www.nice.org.uk\/news\/articles\/changes-to-nice-s-cost-effectiveness-thresholds-confirmed"},{"key":"e_1_3_7_70_1","unstructured":"World Health Organization. Strategic plan for coronavirus disease threat management. Advancing integration sustainability and equity 2025\u20132030. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/7faee4ba-a6fd-4926-b57a-8b0247a57db2\/content"},{"key":"e_1_3_7_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-025-12878-4"},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075495"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae551"},{"key":"e_1_3_7_74_1","doi-asserted-by":"publisher","DOI":"10.3390\/nursrep13010022"},{"key":"e_1_3_7_75_1","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v13.i4.191"},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/nicc.12759"},{"key":"e_1_3_7_77_1","doi-asserted-by":"publisher","DOI":"10.1177\/17511437241312113"},{"key":"e_1_3_7_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-021-02175-z"},{"key":"e_1_3_7_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2469648"},{"key":"e_1_3_7_80_1","unstructured":"ClinicalTrials.gov NCT05576662. Paxlovid for treatment of long Covid (STOP-PASC). 2025. https:\/\/clinicaltrials.gov\/study\/NCT05576662."},{"key":"e_1_3_7_81_1","unstructured":"ClinicalTrials.gov NCT05668091. A decentralized randomized phase 2 efficacy and safety study of nirmatrelvir\/\u200britonavir in adults with long COVID. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05668091"},{"key":"e_1_3_7_82_1","unstructured":"ClinicalTrials.gov NCT05852873. PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway (PanoramicNOR). 2026. https:\/\/clinicaltrials.gov\/study\/NCT05852873"},{"key":"e_1_3_7_83_1","unstructured":"Our World in Data. SARS-CoV-2 sequences by variant. 2025. https:\/\/ourworldindata.org\/grapher\/covid-variants-bar"},{"key":"e_1_3_7_84_1","unstructured":"Infectious Diseases Society of America. IDSA Guidelines on the treatment and management of patients with COVID-19. 2025. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2695551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13696998.2026.2695551","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2695551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:22:17Z","timestamp":1783354937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2695551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2695551"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2695551","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}